Milan Radovich on ctDNA After Neoadjuvant Chemotherapy and Recurrence in TNBC – The ASCO Post

Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse after receiving preoperative chemotherapy can be risk-stratified based on the presence of minimal residual disease as determined by circulating tumor DNA and circulating tumor cells (Abstract GS5-02). …

Read the full article here

Related Articles